Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose rituximab plus CHOP versus standard-dose rituximab plus CHOP in newly diagnosed advanced male DLBCL
ChiCTR2400089468Phase 3Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Modified progression-free survival. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2400089468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089468.